The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pharmacogenetic study in metastatic colorectal cancer (CRC) patients receiving third-line panitumumab-irinotecan: A GERCOR ancillary study.
Marie-Christine Etienne-Grimaldi
No relevant relationships to disclose
Laurence Llorca
No relevant relationships to disclose
Patricia Formento
No relevant relationships to disclose
Benoist Chibaudel
No relevant relationships to disclose
Christophe Tournigand
Honoraria - Amgen
May Mabro
No relevant relationships to disclose
Jean-Baptiste Bachet
No relevant relationships to disclose
Helene Blons
No relevant relationships to disclose
Pierre Laurent-Puig
Consultant or Advisory Role - Amgen
Jean-Louis Formento
No relevant relationships to disclose
Aimery De Gramont
Consultant or Advisory Role - Amgen
Thierry Andre
Consultant or Advisory Role - Amgen
Honoraria - Merck Serono; Roche
Gerard A. Milano
No relevant relationships to disclose